WEBSITE BSE:544491 NSE: GEMAROMA Inc. Year: 1997 Industry: Chemicals My Bucket: Add Stock
Last updated: 15:56
Gem Aromatics Ltd. is an Indian manufacturer of specialty ingredients — including essential oils, aroma chemicals and value‑added derivatives — with a track record spanning over two decades. The company’s product portfolio covers mint and mint‑derivatives, clove and clove‑derivatives, phenol‑based chemicals, and other natural / synthetic ingredients. These find application across a wide array of industries such as oral care, cosmetics, nutraceuticals, pharmaceuticals, wellness, personal care and aromatherapy/therapeutics. Gem Aro...Read More
Gem Aromatics Ltd. is an Indian manufacturer of specialty ingredients — including essential oils, aroma chemicals and value‑added derivatives — with a track record spanning over two decades. The company’s product portfolio covers mint and mint‑derivatives, clove and clove‑derivatives, phenol‑based chemicals, and other natural / synthetic ingredients. These find application across a wide array of industries such as oral care, cosmetics, nutraceuticals, pharmaceuticals, wellness, personal care and aromatherapy/therapeutics. Gem Aromatics operates multiple manufacturing facilities (located in Uttar Pradesh, Dadra & Nagar Haveli / Daman & Diu, and Gujarat) and maintains an in‑house R&D team that supports product innovation and quality control. As of FY25, the company processed and supplied large volumes of raw essential oils (e.g. Piperita, clove, eucalyptus) and derivatives like Eugenol and DMO, where it holds a leading market share in India. Financially, Gem Aromatics has grown steadily over recent years: its revenue rose from around ₹425 crore in FY23 to approximately ₹505–506 crore in FY25, while profit after tax increased in the same period — indicating healthy margins and improving operational performance. The company serves both domestic and international customers, exporting to multiple countries, and services a broad base of clients including several major consumer‑goods and personal‑care firms. With a diversified product range, strong manufacturing plus R&D capabilities, global export footprint and steady financials, Gem Aromatics is positioned as a leading speciality‑ingredients supplier in India, catering to growing demand in cosmetics, wellness, personal care and related health‑oriented segments. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹873 Cr.
Stock P/E 16.3
P/B 1.9
Current Price ₹167.1
Book Value ₹ 86.2
Face Value 2
52W High ₹349
Dividend Yield 0%
52W Low ₹ 133.1
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Jun 2024 | Sep 2024 | Dec 2024 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|
| Net Sales | 93 | 112 | 97 | 88 | 90 | 79 |
| Other Income | 1 | 1 | 0 | 1 | 1 | -2 |
| Total Income | 94 | 113 | 97 | 89 | 91 | 77 |
| Total Expenditure | 78 | 97 | 84 | 73 | 86 | 72 |
| Operating Profit | 15 | 16 | 14 | 16 | 4 | 5 |
| Interest | 1 | 1 | 2 | 4 | 3 | 3 |
| Depreciation | 2 | 2 | 2 | 2 | 3 | 9 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 12 | 13 | 9 | 11 | -3 | -6 |
| Provision for Tax | 4 | 3 | 2 | 3 | 0 | -1 |
| Profit After Tax | 9 | 10 | 7 | 8 | -3 | -5 |
| Adjustments | 0 | 0 | 0 | -0 | 0 | 0 |
| Profit After Adjustments | 9 | 10 | 7 | 8 | -3 | -5 |
| Adjusted Earnings Per Share | 1.8 | 2.1 | 1.6 | 1.7 | -0.5 | -1 |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|
| Net Sales | 314 | 425 | 452 | 504 | 354 |
| Other Income | 3 | 0 | 2 | 2 | 0 |
| Total Income | 317 | 425 | 454 | 506 | 354 |
| Total Expenditure | 265 | 359 | 374 | 416 | 315 |
| Operating Profit | 52 | 66 | 80 | 90 | 39 |
| Interest | 3 | 6 | 6 | 8 | 12 |
| Depreciation | 4 | 5 | 6 | 7 | 16 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 44 | 56 | 68 | 75 | 11 |
| Provision for Tax | 13 | 11 | 17 | 21 | 4 |
| Profit After Tax | 31 | 45 | 50 | 53 | 7 |
| Adjustments | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 31 | 45 | 50 | 53 | 7 |
| Adjusted Earnings Per Share | 6.7 | 9.5 | 10.7 | 11.4 | 1.8 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 12% | 17% | 0% | 0% |
| Operating Profit CAGR | 13% | 20% | 0% | 0% |
| PAT CAGR | 6% | 20% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | NA% | NA% | NA% | NA% |
| ROE Average | 21% | 24% | 24% | 24% |
| ROCE Average | 20% | 23% | 23% | 23% |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Shareholder's Funds | 138 | 180 | 231 | 284 |
| Minority's Interest | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 24 | 69 |
| Other Non-Current Liabilities | 1 | -0 | -1 | 0 |
| Total Current Liabilities | 101 | 115 | 114 | 180 |
| Total Liabilities | 240 | 295 | 367 | 533 |
| Fixed Assets | 36 | 36 | 50 | 54 |
| Other Non-Current Assets | 2 | 15 | 37 | 135 |
| Total Current Assets | 202 | 244 | 280 | 343 |
| Total Assets | 240 | 295 | 367 | 533 |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 8 | 6 | 11 | 16 |
| Cash Flow from Operating Activities | -5 | 15 | 40 | -25 |
| Cash Flow from Investing Activities | -14 | -14 | -51 | -93 |
| Cash Flow from Financing Activities | 18 | 6 | 15 | 103 |
| Net Cash Inflow / Outflow | -1 | 7 | 4 | -15 |
| Closing Cash & Cash Equivalent | 6 | 11 | 16 | 1 |
| # | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Earnings Per Share (Rs) | 6.66 | 9.53 | 10.69 | 11.39 |
| CEPS(Rs) | 7.58 | 10.55 | 12.03 | 12.96 |
| DPS(Rs) | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 29.49 | 38.32 | 49.2 | 60.61 |
| Core EBITDA Margin(%) | 15.64 | 15.58 | 17.32 | 17.55 |
| EBIT Margin(%) | 15.1 | 14.53 | 16.33 | 16.43 |
| Pre Tax Margin(%) | 14.11 | 13.2 | 14.94 | 14.83 |
| PAT Margin (%) | 9.92 | 10.52 | 11.07 | 10.59 |
| Cash Profit Margin (%) | 11.3 | 11.64 | 12.46 | 12.05 |
| ROA(%) | 13.01 | 16.71 | 15.13 | 11.86 |
| ROE(%) | 22.57 | 28.12 | 24.44 | 20.75 |
| ROCE(%) | 22.07 | 25.51 | 24.2 | 19.53 |
| Receivable days | 45.88 | 51.19 | 50.41 | 67.47 |
| Inventory Days | 155.76 | 118.85 | 127.86 | 123.34 |
| Payable days | 26.79 | 22.21 | 21.43 | 20.46 |
| PER(x) | 0 | 0 | 0 | 0 |
| Price/Book(x) | 0 | 0 | 0 | 0 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.23 | 0.19 | 0.23 | 0.46 |
| EV/Core EBITDA(x) | 1.39 | 1.21 | 1.3 | 2.55 |
| Net Sales Growth(%) | 0 | 35.14 | 6.51 | 11.38 |
| EBIT Growth(%) | 0 | 30.02 | 19.66 | 12.09 |
| PAT Growth(%) | 0 | 43.24 | 12.16 | 6.55 |
| EPS Growth(%) | 0 | 43.24 | 12.16 | 6.55 |
| Debt/Equity(x) | 0.56 | 0.5 | 0.48 | 0.78 |
| Current Ratio(x) | 2.01 | 2.12 | 2.47 | 1.91 |
| Quick Ratio(x) | 0.68 | 0.88 | 0.93 | 0.98 |
| Interest Cover(x) | 15.26 | 10.94 | 11.78 | 10.24 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 |
| # | Jun 2025 | Aug 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Promoter | 55.06 | 55.06 | 55.06 | 55.06 | 57.01 |
| FII | 2.93 | 2.93 | 2.01 | 0.79 | 1.06 |
| DII | 9.8 | 9.8 | 6.56 | 4.59 | 4.81 |
| Public | 32.21 | 32.21 | 36.36 | 39.55 | 37.12 |
| Others | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2025 | Aug 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Promoter | 2.88 | 2.88 | 2.88 | 2.88 | 2.98 |
| FII | 0.15 | 0.15 | 0.11 | 0.04 | 0.06 |
| DII | 0.51 | 0.51 | 0.34 | 0.24 | 0.25 |
| Public | 1.68 | 1.68 | 1.9 | 2.07 | 1.94 |
| Others | 0 | 0 | 0 | 0 | 0 |
| Total | 5.22 | 5.22 | 5.22 | 5.22 | 5.22 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
